Stryker (SYK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegelsen ...

The first cases with Stryker's Mako Spine robot have been completed ahead of its anticipated launch, Vice President of Investor Relations Jason Beach said in an ...

Stryker's innovative products, like the Mako robot, and strategic acquisitions bolster its market position and future growth potential. Despite trading slightly above historical valuations ...

Torrington Community Hospital continues to revolutionize patient care using the Stryker Mako SmartRobotics™ system, which ...

Stryker (NYSE:SYK) shares ticked up after hours on third-quarter results that came in ahead of the consensus forecast on Wall ...

Dr. Sharma’s groundbreaking use of Mako robotic technology in hip and knee replacement has set new standards in NCR. His ...

Argus raised the firm’s price target on Stryker (SYK) to $410 from $380 and keeps a Buy rating on the shares after its Q3 earnings beat. The company has delivered strong operating results through ...

We recently published a list of 8 Most Promising Robotics Stocks According to Hedge Funds. In this article, we are going to ...

We already have the Blueprint software, which is fabulous for surgical preplanning. That Blueprint will feed Mako, and we will do bone preparation, and so it will make a very hard procedure much ...

Stryker CEO Kevin Lobo told investors M&A will be the “number one use of our cash going forward,” while Zimmer Biomet CEO Ivan Tornos emphasized internal product development for growth.